1. Loaded Cynomolgus PD-L1-His on HIS1K Biosensor, can bind Anti-Human PDL1 mAb-Fc with an affinity constant of <10^-3 nM as determined in BLI assay. (Regularly tested) 2. Immobilized Anti-Human PDL1 mAb-Fc at 2μg/ml (100 μl/well)can bind Cynomolgus PD-L1-His. The ED50 of Cynomolgus PD-L1-His is 67.12 ng/ml. (Regularly tested)

PD-L1 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-6xHis tag. The predicted molecular weight is 32-40 KDa and the accession number is G7PSE7.

Cynomolgus

HEK293 Cells

Programmed death ligand 1,programmed cell death 1 ligand 1,PDL1PDCD1 ligand 1,PD-L1B7 homolog 1,PD-L1,PDL1,PDCD1LG1,PDCD1L1,CD274 molecule,CD274 antigenMGC142294,CD274,B7H1PDCD1L1,B7-H1,B7H1,B7-H

Phe19-Thr239

Phe19-Thr239

Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.